Phenylketonuria (PKU)
Screening
Tested By
Tandem mass spectrometry (MS/MS); sensitivity=100%; specificity=99.95% [Schulze: 2003]Overview
Deficiency of phenylalanine hydroxylase (PAH), the enzyme responsible for converting phenylalanine to tyrosine, results in accumulation of phenylalanine (Phe) with toxic effects on brain development.Incidence
The incidence of PKU in the U.S. is approximately 1:23,000 births, although in the African-American population, incidence is about 1:50,000. [Therrell: 2014]Maternal & Family History
Benign forms of PKU can present with minimal elevations of phenylalanine levels (maximal plasma phenylalanine <360 micromolar), cause no symptoms, and require no therapy. Mild forms of phenylketonuria can present with slightly increased phenylalanine levels (maximal plasma phenylalanine 360-1000 micromolar), are usually easy to control with diet, and respond to therapy with sapropterin. Yet, children born to women with PKU are at risk for "maternal PKU" because high levels of phenylalanine are teratogenic.Elevated phenylalanine levels can be caused by defects in the synthesis or recycling of tetrahydrobiopterin, an essential co-factor of phenylalanine hydroxylase. Since tetrahydrobiopterin is also a cofactor of other enzymes involved in neurotransmitter synthesis, at-risk patients need to be identified as soon as possible to start appropriate therapy.
Clinical Characteristics
With treatment by early introduction and maintenance of special diet, normal IQ and development can be expected. Without treatment, patients with classic PKU have no symptoms at birth, but usually develop them by 6 months of age.Initial symptoms may include:
- A musty or "mousy" odor of the body and urine
- Developmental delays in sitting, crawling, and standing
- Microcephaly
- Decreased skin and hair pigmentation (due to lack of tyrosine)
- Eczema
- Seizures
- Profound mental retardation
Follow-up Testing after Positive Screen
Quantitative plasma amino acid analysis, red blood cell DHPR assay; urine neopterin profile (the latter two tests to exclude defects in tetrahydrobiopterin synthesis or recycling); DNA testing for PAH gene mutationsPrimary Care Management
Upon Notification of the + Screen
- Contact the family and evaluate the infant for any concerning symptoms.
- Provide urgent treatment/referral for any significant symptoms or seizures. See the ACT Sheet for PKU (ACMG) (
351 KB) for additional information.
- Confirm the diagnosis, work with the following service(s): Newborn Screening Services (see NM providers [1]);
- Evaluate and continue ongoing collaborative management, consult the following service(s): Pediatric Genetics (see NM providers [4]).
If the Diagnosis is Confirmed
- Educate the family about signs, symptoms, and the need for urgent care if the infant becomes ill (see PKU - Information for Parents (STAR-G)).
- Support initiation and maintenance of phenylalanine-restricted diet and supplementation of tyrosine and essential amino acids.
- Avoid the sugar substitute aspartame ("NutraSweet," "Equal," "Sweet Mate," and Canderel") in diet drinks and medications.
- Perform regular blood and urine tests to monitor Phe levels and diet as indicated.
- Assist in management of irreversible consequences as necessary, particularly with developmental and educational interventions.
- See the Portal’s diagnosis and management module for PKU and Pterin Defects.
Specialty Care Collaboration
A dietician may work with the family to devise an optimal approach to dietary management.Resources
Information & Support
For Professionals
Confirmatory Algorithm for PKU (ACMG) ( 73 KB)
Resource for clinicians to help confirm diagnosis; American College of Medical Genetics.
Phenylalanine Hydroxylase Deficiency (GeneReviews)
Detailed information addressing clinical characteristics, diagnosis/testing, management, genetic counseling, and molecular
pathogenesis; from the University of Washington and the National Library of Medicine.
For Parents and Patients
Support
PKU Listserv
Share ideas and concerns with other PKU parents; login required.
General
PKU - Information for Parents (STAR-G)
A fact sheet, written by a genetic counselor and reviewed by metabolic and genetic specialists, for families who have received
an initial diagnosis of a newborn disorder; Screening, Technology and Research in Genetics.
Phenylketonuria (MedlinePlus)
Information for families that includes description, frequency, causes, inheritance, other names, and additional resources;
from the National Library of Medicine.
National Urea Cycle Disorders Foundation
Support and information that includes medical lectures on urea cycle disorders, nutrition and medication resources, and information
about events and conferences.
Tools
ACT Sheet for PKU (ACMG) ( 351 KB)
Contains short-term recommendations for clinical follow-up of the newborn who has screened positive; American College of Medical
Genetics.
Confirmatory Algorithm for PKU (ACMG) ( 73 KB)
Resource for clinicians to help confirm diagnosis; American College of Medical Genetics.
Services for Patients & Families in New Mexico (NM)
| Service Categories | # of providers* in: | NM | NW | Other states (4) (show) | | MT | NV | RI | UT |
|---|---|---|---|---|---|---|---|---|---|
| Newborn Screening Services | 1 | 1 | 4 | 2 | 1 | 3 | |||
| Pediatric Genetics | 4 | 1 | 7 | 4 | 4 | 6 | |||
For services not listed above, browse our Services categories or search our database.
* number of provider listings may vary by how states categorize services, whether providers are listed by organization or individual, how services are organized in the state, and other factors; Nationwide (NW) providers are generally limited to web-based services, provider locator services, and organizations that serve children from across the nation.
Page Bibliography
Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, et al.
Phenylketonuria Scientific Review Conference: state of the science and future research needs.
Mol Genet Metab.
2014;112(2):87-122.
PubMed abstract
Though its title suggests a focus on research, this also represents a consensus on best approaches to care.
Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF.
Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome,
and implications.
Pediatrics.
2003;111(6 Pt 1):1399-406.
PubMed abstract
Therrell BL Jr, Lloyd-Puryear MA, Camp KM, Mann MY.
Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions
for research agenda planning.
Mol Genet Metab.
2014;113(1-2):14-26.
PubMed abstract / Full Text